Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
about
Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat BoundCYP2D6 polymorphisms and their influence on risperidone treatmentGenome-wide prediction of splice-modifying SNPs in human genes using a new analysis pipeline called AASsites.Design and implementation of a randomized controlled trial of genomic counseling for patients with chronic disease.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implicationsComplex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine.Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Complexities of CYP2D6 gene analysis and interpretation.CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR.Assessment of heritable genetic effects using new genetic tools and sentinels in an era of personalized medicine.Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers.Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder
P2860
Q24302187-9848B243-2ABE-492E-9DFC-F26C3207AEBDQ27677093-CCE1FFE2-A94F-4A52-A4F3-ECB15E7FAB59Q28079227-54F12418-01A1-40C8-8321-10632097C81DQ31033205-74E1F194-7B22-47D1-A7AA-CB08B2ECD99AQ33732477-243633AE-C4E9-4191-9804-394660B435DAQ33993320-C7D02031-D406-4913-BBF4-E45DF61C4CD0Q35024501-0DD38C45-F8B0-4F0A-9CAC-FF6256B731DCQ36241478-340FFD58-9161-45E5-AFBE-ECDE635C663DQ36441503-B679297D-75E7-4811-993F-E89487763F2DQ36454174-C46E339D-BBFA-4A77-B102-CC228B2F7F74Q37263885-CEC63271-CDDE-483E-97A9-61385A6047EEQ38154914-EE13C374-7442-414D-910E-47F51074C01DQ43756038-A9C1B3AE-2AE5-4DB3-8555-B811552D9C9DQ44313587-CE53AD24-72F1-4ADC-BDD9-76B805384B29Q46560552-886DE222-BE12-4375-9F90-DAA2441D0B27Q54349187-1E0213A1-4510-4944-B973-5F261EEAB497Q57738148-B627B4CE-FC2A-4FC5-B88F-FC3AEC0C8985
P2860
Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@en
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@nl
type
label
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@en
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@nl
prefLabel
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@en
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@nl
P1476
Pharmacogenetic biomarkers as ...... on the cytochrome P450 system.
@en
P2093
Sarah C Sim
P356
10.1016/J.BBRC.2010.02.162
P407
P577
2010-05-01T00:00:00Z